Do you want to read an article? Please log in or register.
Evaluating the sensitivity of EQ-5D-5L in patients with brain metastases: a secondary analysis of NRG CC001
Further Publications
Related content
COMMENTED
Breast Cancer
A Pooled Analysis of Trastuzumab Deruxtecan in Patients With HER2-Positive Metastatic Breast Cancer With Brain Metastases
★ 3
Recommended and commented by
Prof. Dr Beat Thürlimann, Faculty Member
Ann Oncol
André F, Cortés J, Curigliano G, Modi S, Li W, Park YH, Chung WP, Kim SB, Yamashita T, Pedrini JL, Im SA, Tseng LM, Harbeck N, Krop I, Nakatani S, Tecson K, Ashfaque S, Egorov A, Hurvitz SA
doi: 10.1016/j.annonc.2024.08.2347
Gastrointestinal Cancer
Prognostic value of total tumor volume in patients with colorectal liver metastases: A secondary analysis of the randomized CAIRO5 trial with external cohort validation
Eur J Cancer
Michiel Zeeuw J, Wesdorp NJ, Ali M, Bakker AJJ, Voigt KR, Starmans MPA, Roor J, Kemna R, van Waesberghe JHTM, van den Bergh JE, Nota IMGC, Moos SI, van Dieren S, van Amerongen MJ, Bond MJG, Chapelle T, van Dam RM, Engelbrecht MRW, Gerhards MF, van Gulik TM, Hermans JJ, de Jong KP, Klaase JM, Kok NFM, Leclercq WKG, Liem MSL, van Lienden KP, Quintus Molenaar I, Patijn GA, Rijken AM, Ruers TM, de Wilt JHW, Verpalen IM, Stoker J, Grunhagen DJ, Swijnenburg RJ, Punt CJA, Huiskens J, Verhoef C, Kazemier G
doi: 10.1016/j.ejca.2024.114185
ESMO 2024
Breast Cancer
DESTINY-Breast12: T-DXd proved effective in patients with HER2-positive metastatic breast cancer with or without brain metastases
ESMO 2024
Lung, Respiratory and Thoracic Cancer
TROPION-Lung01: Dato-DXd benefits patients with advanced non-squamous NSCLC with or without brain metastases
Lung, Respiratory and Thoracic Cancer
Brain metastases in clinical trial participants with KRAS-mutated advanced non-small cell lung cancer receiving docetaxel: Pooled data analysis
Lung Cancer
Aptekar J, Jain R, Korytowsky B, Shafquat A, Hendershot J, Talwai A, Itzkovich Y, Padda SK
doi: 10.1016/j.lungcan.2024.107854
Radio-Oncology
Radiomics-based prediction of local control in patients with brain metastases following postoperative stereotactic radiotherapy
Neuro Oncol
Buchner JA, Kofler F, Mayinger M, Christ SM, Brunner TB, Wittig A, Menze B, Zimmer C, Meyer B, Guckenberger M, Andratschke N, El Shafie RA, Debus J, Rogers S, Riesterer O, Schulze K, Feldmann HJ, Blanck O, Zamboglou C, Ferentinos K, Bilger-Zähringer A, Grosu AL, Wolff R, Piraud M, Eitz KA, Combs SE, Bernhardt D, Rueckert D, Wiestler B, Peeken JC
doi: 10.1093/neuonc/noae098
Breast Cancer
Patient-Reported Outcomes for Low-Risk Ductal Carcinoma In Situ: A Secondary Analysis of the COMET Randomized Clinical Trial
JAMA Oncol
Partridge AH, Hyslop T, Rosenberg SM, Bennett AV, Drier S, Jonsson M, Shimada A, Li Y, Li Y, Lynch T, Frank E, Collyar D, Basila D, Pinto D, Weiss A, Wolf A, Norris K, Witten M, Boisvert M, Giuliano A, Larson KE, Yost K, McAuliffe PF, Krie A, Tamirisa N, Darai S, Carey L, Thompson A, Hwang ES, COMET Study Consortium
doi: 10.1001/jamaoncol.2024.6556
Radio-Oncology
Long-Term Results of Stereotactic Radiotherapy in Patients with at Least 10 Brain Metastases at Diagnosis
Cancers (Basel)
Kinj R, Hottinger AF, Böhlen TT, Ozsahin M, Vallet V, Dunet V, Bouchaab H, Peters S, Tuleasca C, Bourhis J, Schiappacasse L
doi: 10.3390/cancers16091742
Breast Cancer
Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: A systematic review and updated meta-analysis
Cancer Treat Rev
Michelon I, Castro CER, Madeira T, Dacoregio MI, Stecca C, Soares LR, Saeed A, Vilbert M, Cavalcante L
doi: 10.1016/j.ctrv.2025.102882